This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Google Scholar Articles by Valle Gottlieb, M. G. Articles by Bodanese, L. C. PubMed PubMed Citation Articles by Valle Gottlieb, M. G. Articles by Bodanese, L. C. Related Collections Lipid Cardiovascular Endocrinology Metabolism

Associations among Metabolic Syndrome, Ischemia, Inflammatory, Oxidatives, and Lipids Biomarkers

Serviço de Cardiologia (M.G.V.G., L.C.B., M.W.), Hospital São Lucas, Pontificia Universidade Católica do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil; Centro de Ciências da Saúde (I.B.M.d.C., R.N.M., M.M.F.D.), Universidade Federal de Santa Maria, 97105-000 Santa Maria, Brazil; and Instituto de Geriatria e Gerontologia (C.H.A.S.), Pontificia Universidade Católica do Rio Grande do Sul, 90610-000 Porto Alegre, Brazil

Address all correspondence and requests for reprints to: Ivana B. M. da Cruz, Centro de Ciências da Saúde, Universidade Federal de Santa Maria, Avenida Roraima 1000, 97105-900, Santa Maria, RS, Brazil. E-mail: ibmcruz{at}hotmail.com.

Context: Metabolic syndrome (MS) is described as a cluster of cardiometabolic risk factors. Studies suggest that ischemia-modified albumin (IMA) is a biomarker of cardiovascular diseases. IMA levels could be associated with cardiometabolic risks and represent a possible indication of microvascular dysfunction in MS patients.

Objective: To confirm this possible association, we evaluated the association between IMA levels and MS.

Design: We performed a case-control study (32 healthy individuals and 74 subjects with MS) to evaluate the association between MS, IMA, and other biomarkers [high-sensitivity C-reactive protein (hs-CRP), oxidized low-density lipoprotein (OxLDL), oxidized low-density lipoprotein autoantibodies (anti-OxLDL), IL-6, lipid profile, and glucose].

Results: The MS group showed higher levels of IMA (0.618 ± 0.1355) as well as higher levels of hs-CRP, OxLDL, anti-OxLDL, and IL-6 than did control subjects (IMA = 0.338 ± 0.0486) (P < 0.01). Multivariate analysis showed that IMA and MS association was independent of sex, age, diabetes mellitus 2, and hypercholesterolemia.

Conclusion: We found an association between IMA and MS. Additional studies including prospective genetic variation approaches need to be performed to help elucidate this association between IMA and MS and its potential clinical role.